Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Effect, Safety and Pharmacoeconomics of First or Second Level-prophylactic Use of PEG-rhG-CSF in Breast Cancer Patients With Medium-high Risk of Febrile Neutropenia During Chemotherapy

NCT03618810 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT03618810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03618810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Effect, Safety and Pharmacoeconomics of First or Second Level-prophylactic Use of PEG-rhG-CSF in Breast Cancer Patients With Medium-high Risk of Febrile Neutropenia During Chemotherapy
Lead sponsor
Zhejiang Cancer Hospital
Phase
Observational
Overall status
Unknown status
Start date
January 20, 2019
Completion date
December 31, 2021
Enrollment
2,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

febrile neutropenia